The determination to include Bharat Biotech’s COVID-19 vaccine Covaxin in WHO emergency use list (EUL) may adopt within four to six weeks. The global health body’s chief scientist Soumya Swaminathan reported to PTI.
Swaminathan said that WHO is analyzing Covaxin as Bharat Biotech are uploading its entire details on the official portal. EUL is a process to recast the process by which unlicensed products used during public health emergencies.
“There is a system followed by EUL and pre-qualification of antibody under a company to finish phase 3 trials. And deliver the whole fact to the regulatory department of WHO tested by an expert advisory group,” Swaminathan stated at a webinar orchestrated by the Centre for Science and Environment (CSE) on Friday, PTI reported.
Now, six antibodies have sanctioned by EUL and have recommendations from Strategic Advisory Group of Experts (SAGE). “We pursue to look at Covaxin. Bharat Biotech has now developed an upload of their testimony on our portal. Which is the next vaccine that scrutinised by our experts committee.
Presently, there are 105 candidate vaccines in clinical assessment out of which 27 are in phase three or four, she stated. There are another 184 candidate antibodies in diagnosis. Most of the antibodies are planned for a two-dose program, she added.
On the Delta variant of the coronavirus, The WHO chief scientist stated it is very contractible. “Two complete doses are necessary for protection against the Delta variant but you can still get the disease and can contract it. This is why masking and other precautions are vital to continue,” she said.
Stay tuned with Artifex.News for further updates. Stay Connected, Stay Informed!
Image Credit: Wikimedia Commons.